-
Je něco špatně v tomto záznamu ?
Palmitoylated PrRP analog decreases body weight in DIO rats but not in ZDF rats
M. Holubová, J. Zemenová, B. Mikulášková, V. Panajotova, J. Stöhr, M. Haluzík, J. Kuneš, B. Železná, L. Maletínská,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
PubMed
26906745
DOI
10.1530/joe-15-0519
Knihovny.cz E-zdroje
- MeSH
- anorektika farmakologie MeSH
- dieta s vysokým obsahem tuků škodlivé účinky MeSH
- experimentální diabetes mellitus metabolismus MeSH
- glukózový toleranční test MeSH
- hormon uvolňující prolaktin analogy a deriváty farmakologie MeSH
- játra účinky léků metabolismus MeSH
- krysa rodu rattus MeSH
- leptinové receptory nedostatek MeSH
- lipoylace MeSH
- messenger RNA genetika metabolismus MeSH
- metabolismus lipidů účinky léků genetika MeSH
- myši MeSH
- obezita farmakoterapie metabolismus patologie MeSH
- potkani Sprague-Dawley MeSH
- potkani Zucker MeSH
- přijímání potravy účinky léků MeSH
- racionální návrh léčiv MeSH
- tělesná hmotnost účinky léků MeSH
- tuková tkáň účinky léků metabolismus MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Anorexigenic neuropeptides produced and acting in the brain have the potential to decrease food intake and ameliorate obesity, but are ineffective after peripheral application, owing to a limited ability to cross the blood-brain barrier. We have designed lipidized analogs of prolactin-releasing peptide (PrRP), which is involved in energy balance regulation as demonstrated by obesity phenotypes of both Prrp-knockout and Prrp receptor-knockout mice. The aim of this study was to characterize the subchronic effect of a palmitoylated PrRP analog in two rat models of obesity and diabetes: diet-induced obese Sprague-Dawley rats and leptin receptor-deficient Zucker diabetic (ZDF) rats. In the rats with diet-induced obesity (DIO), a two-week intraperitoneal treatment with palmitoylated PrRP lowered food intake by 24% and body weight by 8%. This treatment also improved glucose tolerance and tended to decrease leptin levels and adipose tissue masses in a dose-dependent manner. In contrast, in ZDF rats, the same treatment with palmitoylated PrRP lowered food intake but did not significantly affect body weight or glucose tolerance, probably in consequence of severe leptin resistance due to a nonfunctional leptin receptor. Our data indicate a good efficacy of lipidized PrRP in DIO rats. Thus, the strong anorexigenic, body weight-reducing, and glucose tolerance-improving effects make palmitoylated PrRP an attractive candidate for anti-obesity treatment.
1st Faculty of MedicineCharles University Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17024153
- 003
- CZ-PrNML
- 005
- 20170830100951.0
- 007
- ta
- 008
- 170720s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1530/JOE-15-0519 $2 doi
- 035 __
- $a (PubMed)26906745
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Holubová, Martina $u Institute of Organic Chemistry and BiochemistryAcademy of Sciences of the Czech Republic, Prague, Czech Republic.
- 245 10
- $a Palmitoylated PrRP analog decreases body weight in DIO rats but not in ZDF rats / $c M. Holubová, J. Zemenová, B. Mikulášková, V. Panajotova, J. Stöhr, M. Haluzík, J. Kuneš, B. Železná, L. Maletínská,
- 520 9_
- $a Anorexigenic neuropeptides produced and acting in the brain have the potential to decrease food intake and ameliorate obesity, but are ineffective after peripheral application, owing to a limited ability to cross the blood-brain barrier. We have designed lipidized analogs of prolactin-releasing peptide (PrRP), which is involved in energy balance regulation as demonstrated by obesity phenotypes of both Prrp-knockout and Prrp receptor-knockout mice. The aim of this study was to characterize the subchronic effect of a palmitoylated PrRP analog in two rat models of obesity and diabetes: diet-induced obese Sprague-Dawley rats and leptin receptor-deficient Zucker diabetic (ZDF) rats. In the rats with diet-induced obesity (DIO), a two-week intraperitoneal treatment with palmitoylated PrRP lowered food intake by 24% and body weight by 8%. This treatment also improved glucose tolerance and tended to decrease leptin levels and adipose tissue masses in a dose-dependent manner. In contrast, in ZDF rats, the same treatment with palmitoylated PrRP lowered food intake but did not significantly affect body weight or glucose tolerance, probably in consequence of severe leptin resistance due to a nonfunctional leptin receptor. Our data indicate a good efficacy of lipidized PrRP in DIO rats. Thus, the strong anorexigenic, body weight-reducing, and glucose tolerance-improving effects make palmitoylated PrRP an attractive candidate for anti-obesity treatment.
- 650 _2
- $a tuková tkáň $x účinky léků $x metabolismus $7 D000273
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a anorektika $x farmakologie $7 D001067
- 650 _2
- $a tělesná hmotnost $x účinky léků $7 D001835
- 650 _2
- $a experimentální diabetes mellitus $x metabolismus $7 D003921
- 650 _2
- $a dieta s vysokým obsahem tuků $x škodlivé účinky $7 D059305
- 650 _2
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a přijímání potravy $x účinky léků $7 D004435
- 650 _2
- $a glukózový toleranční test $7 D005951
- 650 _2
- $a metabolismus lipidů $x účinky léků $x genetika $7 D050356
- 650 _2
- $a lipoylace $7 D054878
- 650 _2
- $a játra $x účinky léků $x metabolismus $7 D008099
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a obezita $x farmakoterapie $x metabolismus $x patologie $7 D009765
- 650 _2
- $a hormon uvolňující prolaktin $x analogy a deriváty $x farmakologie $7 D056690
- 650 _2
- $a messenger RNA $x genetika $x metabolismus $7 D012333
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Sprague-Dawley $7 D017207
- 650 _2
- $a potkani Zucker $7 D011924
- 650 _2
- $a leptinové receptory $x nedostatek $7 D054411
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Zemenová, Jana $u Institute of Organic Chemistry and BiochemistryAcademy of Sciences of the Czech Republic, Prague, Czech Republic Department of Analytical ChemistryUniversity of Chemistry and Technology, Prague, Czech Republic.
- 700 1_
- $a Mikulášková, Barbora $u Institute of Organic Chemistry and BiochemistryAcademy of Sciences of the Czech Republic, Prague, Czech Republic Institute of PhysiologyAcademy of Sciences of the Czech Republic, Prague, Czech Republic.
- 700 1_
- $a Panajotova, Vladimíra $u Apigenex LimitedPrague, Czech Republic.
- 700 1_
- $a Stöhr, Jiří $u Apigenex LimitedPrague, Czech Republic.
- 700 1_
- $a Haluzík, Martin $u First Faculty of MedicineCharles University, Prague, Czech Republic.
- 700 1_
- $a Kuneš, Jaroslav $u Institute of Organic Chemistry and BiochemistryAcademy of Sciences of the Czech Republic, Prague, Czech Republic Institute of PhysiologyAcademy of Sciences of the Czech Republic, Prague, Czech Republic.
- 700 1_
- $a Železná, Blanka $u Institute of Organic Chemistry and BiochemistryAcademy of Sciences of the Czech Republic, Prague, Czech Republic.
- 700 1_
- $a Maletínská, Lenka $u Institute of Organic Chemistry and BiochemistryAcademy of Sciences of the Czech Republic, Prague, Czech Republic maletin@uochb.cas.cz.
- 773 0_
- $w MED00002653 $t The Journal of endocrinology $x 1479-6805 $g Roč. 229, č. 2 (2016), s. 85-96
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26906745 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20170830101539 $b ABA008
- 999 __
- $a ok $b bmc $g 1239834 $s 985066
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 229 $c 2 $d 85-96 $e 20160223 $i 1479-6805 $m Journal of Endocrinology $n J Endocrinol $x MED00002653
- LZP __
- $a Pubmed-20170720
